Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 301 to 310 of 310 entries
Sorted by: Best Match Show Resources per page
ApoA5 lowers triglyceride levels via suppression of ANGPTL3/8-mediated LPL inhibition.

Journal of lipid research

Chen YQ, Pottanat TG, Zhen EY, Siegel RW, Ehsani M, Qian YW, Konrad RJ.
PMID: 33762177
J Lipid Res. 2021;62:100068. doi: 10.1016/j.jlr.2021.100068. Epub 2021 Mar 21.

Triglyceride (TG) molecules represent the major storage form of fatty acids, and TG metabolism is essential to human health. However, the mechanistic details surrounding TG metabolism are complex and incompletely elucidated. Although it is known that angiopoietin-like protein 8...

Cite
Chen YQ, Pottanat TG, Zhen EY, et al. ApoA5 lowers triglyceride levels via suppression of ANGPTL3/8-mediated LPL inhibition. J Lipid Res. 2021;62:100068doi: 10.1016/j.jlr.2021.100068.
Chen, Y. Q., Pottanat, T. G., Zhen, E. Y., Siegel, R. W., Ehsani, M., Qian, Y. W., & Konrad, R. J. (2021). ApoA5 lowers triglyceride levels via suppression of ANGPTL3/8-mediated LPL inhibition. Journal of lipid research, 62100068. https://doi.org/10.1016/j.jlr.2021.100068
Chen, Yan Q, et al. "ApoA5 lowers triglyceride levels via suppression of ANGPTL3/8-mediated LPL inhibition." Journal of lipid research vol. 62 (2021): 100068. doi: https://doi.org/10.1016/j.jlr.2021.100068
Chen YQ, Pottanat TG, Zhen EY, Siegel RW, Ehsani M, Qian YW, Konrad RJ. ApoA5 lowers triglyceride levels via suppression of ANGPTL3/8-mediated LPL inhibition. J Lipid Res. 2021;62:100068. doi: 10.1016/j.jlr.2021.100068. Epub 2021 Mar 21. PMID: 33762177; PMCID: PMC8079461.
Copy Download .nbib Format: NLM
Resting innate-like B cells leverage sustained Notch2/mTORC1 signaling to achieve rapid and mitosis-independent plasma cell differentiation.

The Journal of clinical investigation

Gaudette BT, Roman CJ, Ochoa TA, Gómez Atria D, Jones DD, Siebel CW, Maillard I, Allman D.
PMID: 34473651
J Clin Invest. 2021 Oct 15;131(20). doi: 10.1172/JCI151975.

Little is known about how cells regulate and integrate distinct biosynthetic pathways governing differentiation and cell division. For B lineage cells it is widely accepted that activated cells must complete several rounds of mitosis before yielding antibody-secreting plasma cells....

Cite
Gaudette BT, Roman CJ, Ochoa TA, et al. Resting innate-like B cells leverage sustained Notch2/mTORC1 signaling to achieve rapid and mitosis-independent plasma cell differentiation. J Clin Invest. 2021;131(20)doi: 10.1172/JCI151975.
Gaudette, B. T., Roman, C. J., Ochoa, T. A., Gómez Atria, D., Jones, D. D., Siebel, C. W., Maillard, I., & Allman, D. (2021). Resting innate-like B cells leverage sustained Notch2/mTORC1 signaling to achieve rapid and mitosis-independent plasma cell differentiation. The Journal of clinical investigation, 131(20), . https://doi.org/10.1172/JCI151975
Gaudette, Brian T, et al. "Resting innate-like B cells leverage sustained Notch2/mTORC1 signaling to achieve rapid and mitosis-independent plasma cell differentiation." The Journal of clinical investigation vol. 131,20 (2021). doi: https://doi.org/10.1172/JCI151975
Gaudette BT, Roman CJ, Ochoa TA, Gómez Atria D, Jones DD, Siebel CW, Maillard I, Allman D. Resting innate-like B cells leverage sustained Notch2/mTORC1 signaling to achieve rapid and mitosis-independent plasma cell differentiation. J Clin Invest. 2021 Oct 15;131(20). doi: 10.1172/JCI151975. PMID: 34473651; PMCID: PMC8516456.
Copy Download .nbib Format: NLM
Imaging.

The Journal of urology

Siegel C.
PMID: 34915719
J Urol. 2021 Dec 17;101097JU0000000000002376. doi: 10.1097/JU.0000000000002376. Epub 2021 Dec 17.

No abstract available.

Cite
Siegel C. Imaging. J Urol. 2021;101097JU0000000000002376doi: 10.1097/JU.0000000000002376.
Siegel, C. (2021). Imaging. The Journal of urology, 101097JU0000000000002376. https://doi.org/10.1097/JU.0000000000002376
Siegel, Cary. "Imaging." The Journal of urology vol. (2021): 101097JU0000000000002376. doi: https://doi.org/10.1097/JU.0000000000002376
Siegel C. Imaging. J Urol. 2021 Dec 17;101097JU0000000000002376. doi: 10.1097/JU.0000000000002376. Epub 2021 Dec 17. PMID: 34915719.
Copy Download .nbib Format: NLM
Quality of Care Program Reduces Unplanned Health Care Utilization in Patients With Inflammatory Bowel Disease.

The American journal of gastroenterology

Melmed GY, Oliver B, Hou JK, Lum D, Singh S, Crate D, Almario C, Bray H, Bresee C, Gerich M, Gerner D, Heagy E, Holthoff M, Hudesman D, McCutcheon Adams K, Mattar MC, Metwally M, Nelson E, Ostrov A, Rubin DT, Scott F, Samir S, van Deen W, Younes Z, Oberai R, Weaver A, Siegel CA.
PMID: 34797226
Am J Gastroenterol. 2021 Nov 19; doi: 10.14309/ajg.0000000000001547. Epub 2021 Nov 19.

INTRODUCTION: There is significant variation in processes and outcomes of care for patients with inflammatory bowel disease (IBD), suggesting opportunities to improve quality of care. We aimed to determine whether a structured quality of care program can improve IBD...

Cite
Melmed GY, Oliver B, Hou JK, et al. Quality of Care Program Reduces Unplanned Health Care Utilization in Patients With Inflammatory Bowel Disease. Am J Gastroenterol. 2021;doi: 10.14309/ajg.0000000000001547.
Melmed, G. Y., Oliver, B., Hou, J. K., Lum, D., Singh, S., Crate, D., Almario, C., Bray, H., Bresee, C., Gerich, M., Gerner, D., Heagy, E., Holthoff, M., Hudesman, D., McCutcheon Adams, K., Mattar, M. C., Metwally, M., Nelson, E., Ostrov, A., Rubin, D. T., Scott, F., Samir, S., van Deen, W., Younes, Z., Oberai, R., Weaver, A., Siegel, C. A. (2021). Quality of Care Program Reduces Unplanned Health Care Utilization in Patients With Inflammatory Bowel Disease. The American journal of gastroenterology, . https://doi.org/10.14309/ajg.0000000000001547
Melmed, Gil Y, et al. "Quality of Care Program Reduces Unplanned Health Care Utilization in Patients With Inflammatory Bowel Disease." The American journal of gastroenterology vol. (2021). doi: https://doi.org/10.14309/ajg.0000000000001547
Melmed GY, Oliver B, Hou JK, Lum D, Singh S, Crate D, Almario C, Bray H, Bresee C, Gerich M, Gerner D, Heagy E, Holthoff M, Hudesman D, McCutcheon Adams K, Mattar MC, Metwally M, Nelson E, Ostrov A, Rubin DT, Scott F, Samir S, van Deen W, Younes Z, Oberai R, Weaver A, Siegel CA. Quality of Care Program Reduces Unplanned Health Care Utilization in Patients With Inflammatory Bowel Disease. Am J Gastroenterol. 2021 Nov 19; doi: 10.14309/ajg.0000000000001547. Epub 2021 Nov 19. PMID: 34797226.
Copy Download .nbib Format: NLM
Point-of-care dashboards promote coproduction of healthcare services for patients with inflammatory bowel disease.

International journal for quality in health care : journal of the International Society for Quality in Health Care

Van Citters AD, Holthoff MM, Kennedy AM, Melmed GY, Oberai R, Siegel CA, Weaver A, Nelson EC.
PMID: 34849970
Int J Qual Health Care. 2021 Nov 29;33:ii40-ii47. doi: 10.1093/intqhc/mzab067.

BACKGROUND: Coproduction of healthcare services by patients and professionals is seen as an increasingly important mechanism to support person-centred care delivery. Coproduction invites a deeper understanding of what persons sometimes called 'patients' bring to development of a service. Yet,...

Cite
Van Citters AD, Holthoff MM, Kennedy AM, et al. Point-of-care dashboards promote coproduction of healthcare services for patients with inflammatory bowel disease. Int J Qual Health Care. 2021;33:ii40-ii47doi: 10.1093/intqhc/mzab067.
Van Citters, A. D., Holthoff, M. M., Kennedy, A. M., Melmed, G. Y., Oberai, R., Siegel, C. A., Weaver, A., & Nelson, E. C. (2021). Point-of-care dashboards promote coproduction of healthcare services for patients with inflammatory bowel disease. International journal for quality in health care : journal of the International Society for Quality in Health Care, 33ii40-ii47. https://doi.org/10.1093/intqhc/mzab067
Van Citters, Aricca D, et al. "Point-of-care dashboards promote coproduction of healthcare services for patients with inflammatory bowel disease." International journal for quality in health care : journal of the International Society for Quality in Health Care vol. 33 (2021): ii40-ii47. doi: https://doi.org/10.1093/intqhc/mzab067
Van Citters AD, Holthoff MM, Kennedy AM, Melmed GY, Oberai R, Siegel CA, Weaver A, Nelson EC. Point-of-care dashboards promote coproduction of healthcare services for patients with inflammatory bowel disease. Int J Qual Health Care. 2021 Nov 29;33:ii40-ii47. doi: 10.1093/intqhc/mzab067. PMID: 34849970.
Copy Download .nbib Format: NLM
Imaging.

The Journal of urology

Siegel C.
PMID: 34496605
J Urol. 2021 Dec;206(6):1496. doi: 10.1097/JU.0000000000002225. Epub 2021 Sep 09.

No abstract available.

Cite
Siegel C. Imaging. J Urol. 2021;206(6):1496doi: 10.1097/JU.0000000000002225.
Siegel, C. (2021). Imaging. The Journal of urology, 206(6), 1496. https://doi.org/10.1097/JU.0000000000002225
Siegel, Cary. "Imaging." The Journal of urology vol. 206,6 (2021): 1496. doi: https://doi.org/10.1097/JU.0000000000002225
Siegel C. Imaging. J Urol. 2021 Dec;206(6):1496. doi: 10.1097/JU.0000000000002225. Epub 2021 Sep 09. PMID: 34496605.
Copy Download .nbib Format: NLM
Re: Urinary bladder: normal appearance and mimics of malignancy at CT urography.

The Journal of urology

Siegel C.
PMID: 22579173
J Urol. 2012 Jun;187(6):2025. doi: 10.1016/j.juro.2012.02.2518. Epub 2012 Apr 11.

No abstract available.

Cite
Siegel C. Re: Urinary bladder: normal appearance and mimics of malignancy at CT urography. J Urol. 2012;187(6):2025doi: 10.1016/j.juro.2012.02.2518.
Siegel, C. (2012). Re: Urinary bladder: normal appearance and mimics of malignancy at CT urography. The Journal of urology, 187(6), 2025. https://doi.org/10.1016/j.juro.2012.02.2518
Siegel, Cary. "Re: Urinary bladder: normal appearance and mimics of malignancy at CT urography." The Journal of urology vol. 187,6 (2012): 2025. doi: https://doi.org/10.1016/j.juro.2012.02.2518
Siegel C. Re: Urinary bladder: normal appearance and mimics of malignancy at CT urography. J Urol. 2012 Jun;187(6):2025. doi: 10.1016/j.juro.2012.02.2518. Epub 2012 Apr 11. PMID: 22579173.
Copy Download .nbib Format: NLM
Somatotopic Specificity of Perceptual and Neurophysiological Changes Associated with Visuo-proprioceptive Realignment.

Cerebral cortex (New York, N.Y. : 1991)

Mirdamadi JL, Seigel CR, Husch SD, Block HJ.
PMID: 34424950
Cereb Cortex. 2021 Aug 23; doi: 10.1093/cercor/bhab280. Epub 2021 Aug 23.

When visual and proprioceptive estimates of hand position disagree (e.g., viewing the hand underwater), the brain realigns them to reduce mismatch. This perceptual change is reflected in primary motor cortex (M1) excitability, suggesting potential relevance for hand movement. Here,...

Cite
Mirdamadi JL, Seigel CR, Husch SD, et al. Somatotopic Specificity of Perceptual and Neurophysiological Changes Associated with Visuo-proprioceptive Realignment. Cereb Cortex. 2021;doi: 10.1093/cercor/bhab280.
Mirdamadi, J. L., Seigel, C. R., Husch, S. D., & Block, H. J. (2021). Somatotopic Specificity of Perceptual and Neurophysiological Changes Associated with Visuo-proprioceptive Realignment. Cerebral cortex (New York, N.Y. : 1991), . https://doi.org/10.1093/cercor/bhab280
Mirdamadi, Jasmine L, et al. "Somatotopic Specificity of Perceptual and Neurophysiological Changes Associated with Visuo-proprioceptive Realignment." Cerebral cortex (New York, N.Y. : 1991) vol. (2021). doi: https://doi.org/10.1093/cercor/bhab280
Mirdamadi JL, Seigel CR, Husch SD, Block HJ. Somatotopic Specificity of Perceptual and Neurophysiological Changes Associated with Visuo-proprioceptive Realignment. Cereb Cortex. 2021 Aug 23; doi: 10.1093/cercor/bhab280. Epub 2021 Aug 23. PMID: 34424950.
Copy Download .nbib Format: NLM
Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Lukin D, Faleck D, Xu R, Zhang Y, Weiss A, Aniwan S, Kadire S, Tran G, Rahal M, Winters A, Chablaney S, Koliani-Pace JL, Meserve J, Campbell JP, Kochhar G, Bohm M, Varma S, Fischer M, Boland B, Singh S, Hirten R, Ungaro R, Lasch K, Shmidt E, Jairath V, Hudesman D, Chang S, Swaminath A, Shen B, Kane S, Loftus EV, Sands BE, Colombel JF, Siegel CA, Sandborn WJ, Dulai PS.
PMID: 33039584
Clin Gastroenterol Hepatol. 2022 Jan;20(1):126-135. doi: 10.1016/j.cgh.2020.10.003. Epub 2020 Oct 08.

BACKGROUND & AIMS: We aimed to compare safety and effectiveness of vedolizumab to tumor necrosis factor (TNF)-antagonist therapy in ulcerative colitis in routine practice.METHODS: A multicenter, retrospective, observational cohort study (May 2014 to December 2017) of ulcerative colitis patients...

Cite
Lukin D, Faleck D, Xu R, et al. Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020;20(1):126-135doi: 10.1016/j.cgh.2020.10.003.
Lukin, D., Faleck, D., Xu, R., Zhang, Y., Weiss, A., Aniwan, S., Kadire, S., Tran, G., Rahal, M., Winters, A., Chablaney, S., Koliani-Pace, J. L., Meserve, J., Campbell, J. P., Kochhar, G., Bohm, M., Varma, S., Fischer, M., Boland, B., Singh, S., Hirten, R., Ungaro, R., Lasch, K., Shmidt, E., Jairath, V., Hudesman, D., Chang, S., Swaminath, A., Shen, B., Kane, S., Loftus, E. V., Sands, B. E., Colombel, J. F., Siegel, C. A., Sandborn, W. J., & Dulai, P. S. (2022). Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 20(1), 126-135. https://doi.org/10.1016/j.cgh.2020.10.003
Lukin, Dana, et al. "Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis." Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association vol. 20,1 (2022): 126-135. doi: https://doi.org/10.1016/j.cgh.2020.10.003
Lukin D, Faleck D, Xu R, Zhang Y, Weiss A, Aniwan S, Kadire S, Tran G, Rahal M, Winters A, Chablaney S, Koliani-Pace JL, Meserve J, Campbell JP, Kochhar G, Bohm M, Varma S, Fischer M, Boland B, Singh S, Hirten R, Ungaro R, Lasch K, Shmidt E, Jairath V, Hudesman D, Chang S, Swaminath A, Shen B, Kane S, Loftus EV, Sands BE, Colombel JF, Siegel CA, Sandborn WJ, Dulai PS. Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis. Clin Gastroenterol Hepatol. 2022 Jan;20(1):126-135. doi: 10.1016/j.cgh.2020.10.003. Epub 2020 Oct 08. PMID: 33039584; PMCID: PMC8026779.
Copy Download .nbib Format: NLM
Imaging.

The Journal of urology

Siegel C.
PMID: 34406024
J Urol. 2021 Nov;206(5):1305-1306. doi: 10.1097/JU.0000000000002160. Epub 2021 Aug 18.

No abstract available.

Cite
Siegel C. Imaging. J Urol. 2021;206(5):1305-1306doi: 10.1097/JU.0000000000002160.
Siegel, C. (2021). Imaging. The Journal of urology, 206(5), 1305-1306. https://doi.org/10.1097/JU.0000000000002160
Siegel, Cary. "Imaging." The Journal of urology vol. 206,5 (2021): 1305-1306. doi: https://doi.org/10.1097/JU.0000000000002160
Siegel C. Imaging. J Urol. 2021 Nov;206(5):1305-1306. doi: 10.1097/JU.0000000000002160. Epub 2021 Aug 18. PMID: 34406024.
Copy Download .nbib Format: NLM
Showing 301 to 310 of 310 entries